PCN2- DOSES OF OLANZPINE, RISPERIDONE, AND HALOPERIDOL IN CLINICAL PRACTICE- RESULTS OF A PROSPECTIVE PHARMACOEOPIDEMIOGICAL STUDY (EFESO)
Sep 1, 1999, 00:00 AM
10.1016/S1098-3015(10)75842-3
https://www.valueinhealthjournal.com/article/S1098-3015(10)75842-3/fulltext
Section Title :
Section Order :
88
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)75842-3&doi=10.1016/S1098-3015(10)75842-3